

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* SHOOTER ERIC M			2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [REGN]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/12/2014			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
777 OLD SAW MILL RIVER ROAD			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) TARRYTOWN NY 10591								
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/12/2014		M		5,000	A	\$177.82	5,000	D	
Common Stock	02/12/2014		M		5,000	A	\$57.11	10,000	D	
Common Stock	02/12/2014		M		5,000	A	\$33.42	15,000	D	
Common Stock	02/12/2014		S		12,878	D	\$320.41 ⁽¹⁾	2,122	D	
Common Stock	02/12/2014		S		2,122	D	\$321.22 ⁽²⁾	0	D	
Common Stock	02/12/2014		C		7,000	A	\$0.0	7,000	I	by Trust
Common Stock	02/12/2014		G ⁽³⁾	V	7,000	D	\$0.0	0	I	by Trust
Common Stock								2,500	I	GRAT self
Common Stock								2,500	I	GRAT spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Class A Stock	⁽⁴⁾	02/12/2014		C		7,000		⁽⁵⁾	⁽⁶⁾	Common Stock	7,000	\$0.0	85	I	by Trust
Non-Qualified Stock Option (right to buy)	\$33.42	02/12/2014		M		5,000		⁽⁷⁾	01/03/2021	Common Stock	5,000	\$0.0	0	D	
Non-Qualified Stock Option (right to buy)	\$57.11	02/12/2014		M		5,000		⁽⁷⁾	01/03/2022	Common Stock	5,000	\$0.0	5,000	D	
Non-Qualified Stock Option (right to buy)	\$177.82	02/12/2014		M		5,000		⁽⁷⁾	01/02/2023	Common Stock	5,000	\$0.0	10,000	D	

Explanation of Responses:

1. Represents volume-weighted average price of sales of 12,878 shares of Company stock on February 12, 2014 at prices ranging from \$320.00 to \$320.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.

2. Represents volume-weighted average price of sales of 2,122 shares of Company stock on February 12, 2014 at prices ranging from \$321.00 to \$321.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 12, 2014 at each separate price.

3. Gift of Common Stock to a charitable foundation.

4. Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events or upon election of the shareholder.

5. Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

6. Shares of Class A Stock are convertible at any time on a share-for-share basis into Common Stock.

7. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.

/s/**Eric M. Shooter

02/13/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.